These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 8032961)
21. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer. Chevallier B; Mignot L; Delozier T; Morvan F; Ferme C; Herait P Am J Clin Oncol; 1992 Oct; 15(5):395-8. PubMed ID: 1524040 [TBL] [Abstract][Full Text] [Related]
22. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710 [TBL] [Abstract][Full Text] [Related]
23. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Al-Batran SE; Meerpohl HG; von Minckwitz G; Atmaca A; Kleeberg U; Harbeck N; Lerbs W; Hecker D; Sehouli J; Knuth A; Jager E Oncology; 2006; 70(2):141-6. PubMed ID: 16645327 [TBL] [Abstract][Full Text] [Related]
24. Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years). Basso U; Roma A; Brunello A; Falci C; Fiduccia P; Banzato A; Bononi A; Gusella M; Vamvakas L; Zagonel V; Monfardini S J Geriatr Oncol; 2013 Oct; 4(4):340-5. PubMed ID: 24472477 [TBL] [Abstract][Full Text] [Related]
25. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO. Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J; Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074 [TBL] [Abstract][Full Text] [Related]
26. Phase II clinical evaluation of 4'-epi-doxorubicin. Hurteloup P; Cappelaere P; Armand JP; Mathé G Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956 [TBL] [Abstract][Full Text] [Related]
27. Phase II trial of doxorubicin therapy for advanced islet cell carcinoma. Moertel CG; Lavin PT; Hahn RG Cancer Treat Rep; 1982 Jul; 66(7):1567-9. PubMed ID: 6284361 [TBL] [Abstract][Full Text] [Related]
28. Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer. Dittrich C; Baur M; Mader R; Schlappack O; Dudczak R; Leitha T; Lenzhofer R; Hoffmann S; Vieder L; Heberle U Am J Clin Oncol; 1990; 13 Suppl 1():S29-39. PubMed ID: 1963274 [TBL] [Abstract][Full Text] [Related]
29. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM; Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685 [TBL] [Abstract][Full Text] [Related]
30. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study. Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of pirarubicin in metastatic breast cancer. Kleeberg UR; Reichel L; Wander HE; Beyer JH; Essers U; Fiebig HH; Salewski E; Greifenberg B; Edler L Onkologie; 1990 Jun; 13(3):175-9. PubMed ID: 2204003 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Rose PG; Blessing JA; Lele S; Abulafia O Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630 [TBL] [Abstract][Full Text] [Related]
34. Pirarubicin phase II study in untreated metastatic small-cell lung carcinoma. A cooperative study of the Groupe Français de Pneumo-Cancérologie (GFPC). Kleisbauer JP; Vergeret J; Balmes P; Arnaud A; Taytard A; Targhetta R; Thomas P; Bonnaud F; Poirier R; Touron D Am J Clin Oncol; 1990; 13 Suppl 1():S20-3. PubMed ID: 1963272 [TBL] [Abstract][Full Text] [Related]
36. Phase II trial of 4'-epi-doxorubicin in metastatic colorectal carcinoma. Wils JA Invest New Drugs; 1984; 2(4):397-9. PubMed ID: 6595243 [TBL] [Abstract][Full Text] [Related]
37. Anaphylactic shock due to intravesical administration of pirarubicin hydrochloride for the fifth time. Sakata K; Fukuoka N; Tanabe K; Takenaka M; Iida H J Clin Anesth; 2016 Feb; 28():2-3. PubMed ID: 26796606 [TBL] [Abstract][Full Text] [Related]
38. Phase II study of 5-fluorouracil, pirarubicin and low-dose consecutive administration of cisplatin for advanced and recurrent gastric cancer. Kikuyama S; Inada T; Miyakita M; Ogata Y Jpn J Clin Oncol; 1998 May; 28(5):314-7. PubMed ID: 9703858 [TBL] [Abstract][Full Text] [Related]
39. Phase II trial of esorubicin in patients with advanced colorectal carcinoma. Fiore J; Kemeny N; Raymond V; Young C Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453 [No Abstract] [Full Text] [Related]
40. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Booser DJ; Esteva FJ; Rivera E; Valero V; Esparza-Guerra L; Priebe W; Hortobagyi GN Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]